Kohima News Paper

Major Depressive Disorder Market Trends Analysis, Clinical Activities, Emerging Therapies, and Epidemiology Forecast | Key Companies – Axsome Therapeutics, SAGE Therapeutics, and Minerva Neurosciences

 Breaking News
  • No posts were found

Major Depressive Disorder Market Trends Analysis, Clinical Activities, Emerging Therapies, and Epidemiology Forecast | Key Companies – Axsome Therapeutics, SAGE Therapeutics, and Minerva Neurosciences

April 26
04:25 2022
Major Depressive Disorder Market Trends Analysis, Clinical Activities, Emerging Therapies, and Epidemiology Forecast | Key Companies - Axsome Therapeutics, SAGE Therapeutics, and Minerva Neurosciences
Delveinsight Business Research LLP
DelveInsight’s “Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Major Depressive Disorder Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Major Depressive Disorder market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Major Depressive Disorder Market

Major Depressive Disorder: An Overview

Major Depressive Disorder (MDD), also referred to as depression, is a serious medical illness that disrupts a person’s mood, behavior, and thought processes, apart from degrading physical health.

Major Depressive Disorder Market Key Facts

  • According to the Anxiety & Depression Association, the prevalence of major depressive episodes was higher among adult females (8.7%) compared to males (5.3%). The prevalence of adults with a major depressive episode was highest among individuals aged 18-25 (13.1%).

  • According to the Anxiety & Depression Association of America, In 2017, around 17.3 million aged 18 years or older in the U.S. had experienced at least one major depressive episode in the last year, which represented 6.7% of all American adults. While major depressive disorder can develop at any age, the median age at onset is 32.5 years old.

  • Among the European 5 countries, France had the highest prevalent population of Major Depressive Disorder (MDD), followed by Germany and Spain. On the other hand, the United Kingdom had the lowest prevalent population of Major Depressive Disorder (MDD). 

Major Depressive Disorder Market

The Major Depressive Disorder (MDD) Market Size is expected to increase during the study period owing to the rising prevalent population in the 7MM, along with the expected entry of premium price assets such as nociceptin receptor antagonist, Botox, selective orexin 2 receptor antagonist.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Major Depressive Disorder market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Major Depressive Disorder market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Major Depressive Disorder Epidemiology

The epidemiology section covers insights into the historical and current Major Depressive Disorder patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool, future trends, and assumptions undertaken.

Major Depressive Disorder Epidemiology Segmentation –

  • Prevalent Cases of Major Depressive Disorder

  • Severity-specific Prevalent Pool of Major Depressive Disorder

  • Age-Specific Cases of  Major Depressive Disorder

  • Gender-Specific Prevalent Pool of Major Depressive Disorder

  • Treatable Patient Pool of Major Depressive Disorder

  • Relapse/Refractory Patient Pool of Major Depressive Disorder

Major Depressive Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Major Depressive Disorder market or expected to get launched during the study period. The analysis covers Major Depressive Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Major Depressive Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/major-depressive-disorder-market

Major Depressive Disorder Therapeutics Analysis

The emerging treatment options in the Major Depressive Disorder (MDD) Landscape aim to improve the responses which are inadequate with respect to standard antidepressant therapies.

Some of the key companies in the Major Depressive Disorder Market include:

  • Axsome Therapeutics

  • SAGE therapeutics

  • Johnson & Johnson

  • Minerva Neurosciences

  • Relmada Therapeutics

  • Intra-Cellular Therapies

And many others.

Major Depressive Disorder Therapies covered in the report include:

  • AXS-05

  • SAGE-217

  • REL-1017

  • Seltorexant

  • Lumateperone

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/major-depressive-disorder-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Major Depressive Disorder Competitive Intelligence Analysis

4. Major Depressive Disorder Market Overview at a Glance

5. Major Depressive Disorder Disease Background and Overview

6. Major Depressive Disorder Patient Journey

7. Major Depressive Disorder Epidemiology and Patient Population

8. Major Depressive Disorder Treatment Algorithm, Current Treatment, and Medical Practices

9. Major Depressive Disorder Unmet Needs

10. Key Endpoints of Major Depressive Disorder Treatment

11. Major Depressive Disorder Marketed Products

12. Major Depressive Disorder Emerging Therapies

13. Major Depressive Disorder Seven Major Market Analysis

14. Attribute Analysis

15. Major Depressive Disorder Market Outlook (7 major markets)

16. Major Depressive Disorder Access and Reimbursement Overview

17. KOL Views on the Major Depressive Disorder Market.

18. Major Depressive Disorder Market Drivers

19. Major Depressive Disorder Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/major-depressive-disorder-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Other Latest Reports By DelveInsight

Paraganglioma Market

DelveInsight’s “Paraganglioma Market” report delivers an in-depth understanding of the historical and forecasted epidemiology, the Paraganglioma market size, shares, and trends analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan) as well as the emerging therapies and key companies in the therapeutic domain.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/